Shares of Heska Corp (NASDAQ:HSKA) have earned a consensus rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $86.67.
A number of brokerages recently issued reports on HSKA. Piper Jaffray Companies began coverage on shares of Heska in a research report on Wednesday, September 18th. They set a “neutral” rating and a $68.00 target price for the company. Zacks Investment Research cut shares of Heska from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. BidaskClub upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 27th. Raymond James lowered shares of Heska from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. They noted that the move was a valuation call. Finally, Canaccord Genuity reissued a “buy” rating and set a $105.00 price objective (up previously from $75.00) on shares of Heska in a report on Wednesday, November 6th.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Heska by 0.6% during the 2nd quarter. BlackRock Inc. now owns 1,074,360 shares of the medical research company’s stock worth $91,503,000 after acquiring an additional 6,904 shares during the last quarter. FMR LLC grew its holdings in Heska by 2.0% during the 1st quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after acquiring an additional 8,870 shares during the last quarter. Vanguard Group Inc. grew its holdings in Heska by 1.1% during the 2nd quarter. Vanguard Group Inc. now owns 448,105 shares of the medical research company’s stock worth $38,166,000 after acquiring an additional 5,019 shares during the last quarter. State Street Corp grew its holdings in Heska by 7.0% during the 3rd quarter. State Street Corp now owns 297,775 shares of the medical research company’s stock worth $21,103,000 after acquiring an additional 19,470 shares during the last quarter. Finally, SG Capital Management LLC bought a new stake in Heska during the 3rd quarter worth about $20,182,000. 97.92% of the stock is currently owned by hedge funds and other institutional investors.
Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million. Heska had a net margin of 3.15% and a return on equity of 3.17%. On average, research analysts predict that Heska will post 0.05 EPS for the current fiscal year.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.